Irisin alleviates hepatic steatosis by activating the autophagic SIRT3 pathway
Our findings highlight irisin as a potential therapeutic for hepatic steatosis by modulating autophagy and lipid metabolism, potentially providing a novel therapeutic target for the management of MASLD. Further research is needed to elucidate the underlying mechanisms and explore the potential clinical applications of this approach in the treatment of MASLD.
Authors
- Yunzhi Ni (ORCID: https://orcid.org/0000-0003-2453-2522)
- Anran Ma (ORCID: https://orcid.org/0000-0003-1831-0851)
- Yue Zhou (ORCID: https://orcid.org/0009-0008-9302-3223)
- Yongsheng Chang (ORCID: https://orcid.org/0000-0002-7846-8127)
- Na Zhang (ORCID: https://orcid.org/0000-0001-6978-2731)
- Jia Li (ORCID: https://orcid.org/0000-0002-3108-8645)
- Li Zhang (ORCID: https://orcid.org/0000-0003-2259-0817)
- Qinghua Wang (ORCID: https://orcid.org/0009-0007-1535-0870)
- Zhihong Wang (ORCID: https://orcid.org/0000-0003-3196-1739)
- Di Wu (ORCID: https://orcid.org/0000-0003-1802-4855)
- Ying Zhao (ORCID: https://orcid.org/0000-0001-6228-5433)
Institutions
- Fudan University (CN)
- Fosun Pharma (China) (CN)
- Huashan Hospital (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Chinese Medical Journal
- Published
- 2025-02-18
- DOI
- https://doi.org/10.1097/cm9.0000000000003427
- Citations
- 5
- Primary Topic
- Adipose Tissue and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 5.82